The Business Research Company
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025 /EINPresswire.com/ — The glioblastoma multiforme global market report highlights the significant surge in the market size in recent years. The size is set to grow from $2.50 billion in 2024 to $2.71 billion in 2025, reflecting a compound annual growth rate CAGR of 8.3%. Factors influencing growth in the historic period include increasing incidence of glioblastoma multiforme, improved healthcare infrastructure, enhanced awareness, increased access to advanced therapies, and a burgeoning aging population.
What Comprises The Size of The Glioblastoma Multiforme Market In The Foreseeable Future?
The glioblastoma multiforme market size is expected to see robust growth in the next few years, as it’s projected to increase to $3.69 billion in 2029 at a compound annual growth rate CAGR of 8.1%. The surge in the forecast period can be linked to an increase in cases of brain and other nervous system tumors, greater acceptance of surgical methodologies, rising awareness, early diagnosis of the disease, and a rise in R&D activities. Significant trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalised medicine, AI tools for diagnosis, and technological and scientific developments.
Get Your Free Sample Market Report:
What Drives The Growth Of The Glioblastoma Multiforme Market?
The anticipated growth of the glioblastoma multiforme market can be attributed to the rising cases of brain disorders. A brain disorder, a condition that affects the structure or function of the brain, leads to cognitive, emotional, or physical impairments. Increasing cases of brain disorders are due to aging populations, increased life expectancy, lifestyle factors, and improved diagnostic capabilities. Understanding brain disorders aids in advancing research on glioblastoma multiforme GBM, resulting in better early detection, novel treatments, and improved patient outcomes. Scientists are employing studies of neurological conditions to discover genetic and molecular links that contribute to GBM development.
Order Your Report Now For A Swift Delivery:
Who Are The Major Players In The Glioblastoma Multiforme Market?
Prominent companies operating in the glioblastoma multiforme market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals USA Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, and VBI Vaccines Inc.
What Are The Emerging Trends In The Glioblastoma Multiforme Market?
These key industry players are proactively focusing on the development of advanced therapies, such as CAR T-cell therapies, to meet the unmet medical needs for aggressive cancer. CAR T-cell therapies are a category of immunotherapy that includes the modification of a patient’s T-cells to target and kill cancer cells more effectively.
How Is The Glioblastoma Multiforme Market Segmented?
1 By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2 By Diagnostic Tools: Magnetic Resonance Imaging MRI, Computed Tomography Scan CT Scan, Biopsy, Other Diagnostic Tools
3 By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Fields Therapy, Other Treatment Types
4 By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
These categories also include several subsegments:
1 By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2 By Temozolomide: Branded Temodar, Generic Temozolomide
3 By Carmustine: Injectable Carmustine, Carmustine Wafers Gliadel
4 By Lomustine: Branded Gleostine, Generic Lomustine
5 By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields TTF Therapy
Which Regions Show Major Market Activity?
North America was the largest region in terms of the glioblastoma multiforme market in 2024, while Asia-Pacific is predicted to be the fastest-growing region in the future. The regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurology Devices Global Market Report 2024
Neurology Devices Global Market Report 2024
Neuroprosthetics Global Market Report 2024
Get ahead in the game with The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company offers comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders, we provide the information you need to stay ahead.
Contact us at:
The Business Research Company:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn:
YouTube:
Global Market Model: global-market-model.
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Article originally published on www.einpresswire.com as Rising Cases Of Brain Disorders Fuels Growth In Market
